LTPA2022518I1 - - Google Patents
Info
- Publication number
- LTPA2022518I1 LTPA2022518I1 LTPA2022518C LTPA2022518C LTPA2022518I1 LT PA2022518 I1 LTPA2022518 I1 LT PA2022518I1 LT PA2022518 C LTPA2022518 C LT PA2022518C LT PA2022518 C LTPA2022518 C LT PA2022518C LT PA2022518 I1 LTPA2022518 I1 LT PA2022518I1
- Authority
- LT
- Lithuania
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12170748 | 2012-06-04 | ||
EP13158520 | 2013-03-11 | ||
PCT/IB2013/054567 WO2013182972A1 (en) | 2012-06-04 | 2013-06-03 | Benzimidazole-proline derivatives |
EP13744805.6A EP2855453B1 (en) | 2012-06-04 | 2013-06-03 | Benzimidazole-proline derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
LTPA2022518I1 true LTPA2022518I1 (lt) | 2022-09-26 |
Family
ID=48914370
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP13744805.6T LT2855453T (lt) | 2012-06-04 | 2013-06-03 | Benzimidazolo prolino dariniai |
LTPA2022518C LTPA2022518I1 (lt) | 2012-06-04 | 2022-08-31 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP13744805.6T LT2855453T (lt) | 2012-06-04 | 2013-06-03 | Benzimidazolo prolino dariniai |
Country Status (33)
Country | Link |
---|---|
US (3) | US9732075B2 (lt) |
EP (1) | EP2855453B1 (lt) |
JP (1) | JP5814491B2 (lt) |
KR (3) | KR101946128B1 (lt) |
CN (1) | CN104334544B (lt) |
AR (1) | AR091257A1 (lt) |
AU (1) | AU2013273222B2 (lt) |
BR (1) | BR112014030173B1 (lt) |
CA (1) | CA2873341C (lt) |
CL (1) | CL2014003294A1 (lt) |
CY (1) | CY1118735T1 (lt) |
DK (1) | DK2855453T3 (lt) |
EA (2) | EA028046B1 (lt) |
ES (1) | ES2617863T3 (lt) |
FR (1) | FR22C1047I2 (lt) |
HK (1) | HK1208449A1 (lt) |
HR (1) | HRP20170351T1 (lt) |
HU (2) | HUE031753T2 (lt) |
IL (1) | IL236024A (lt) |
LT (2) | LT2855453T (lt) |
MX (1) | MX354102B (lt) |
MY (1) | MY169986A (lt) |
NL (1) | NL301197I2 (lt) |
NO (1) | NO2022044I1 (lt) |
NZ (1) | NZ703448A (lt) |
PH (1) | PH12014502540A1 (lt) |
PL (1) | PL2855453T3 (lt) |
PT (1) | PT2855453T (lt) |
SG (2) | SG10201702540UA (lt) |
SI (1) | SI2855453T1 (lt) |
TW (2) | TWI510481B (lt) |
WO (1) | WO2013182972A1 (lt) |
ZA (1) | ZA201409422B (lt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5744203B2 (ja) | 2010-08-24 | 2015-07-08 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | オレキシン受容体拮抗薬としてのプロリンスルフォンアミド誘導体 |
TWI510481B (zh) | 2012-06-04 | 2015-12-01 | Actelion Pharmaceuticals Ltd | 苯并咪唑脯胺酸衍生物 |
AU2013328301A1 (en) | 2012-10-10 | 2015-05-28 | Actelion Pharmaceuticals Ltd | Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives |
JP2016510810A (ja) | 2013-03-12 | 2016-04-11 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | オレキシン受容体アンタゴニストとしてのアゼチジンアミド誘導体 |
MX363432B (es) | 2013-07-22 | 2019-03-22 | Idorsia Pharmaceuticals Ltd | Derivados 1-(piperazin-1-il)-2-([1,2,4]triazol-1-il)-etanona. |
UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
PT3077389T (pt) * | 2013-12-03 | 2017-12-15 | Idorsia Pharmaceuticals Ltd | Forma cristalina de (s)-(2-(6-cloro-7-metil-1hbenzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona e a sua utilização como como antagonistas do receptor de orexina |
HUE040555T2 (hu) | 2013-12-04 | 2019-03-28 | Idorsia Pharmaceuticals Ltd | Benzimidazol prolin származékok alkalmazása |
TW201613864A (en) * | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
AU2015220553B2 (en) * | 2014-02-20 | 2019-06-27 | Takeda Pharmaceutical Company Limited | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists |
WO2016113344A1 (en) * | 2015-01-15 | 2016-07-21 | Actelion Pharmaceuticals Ltd | Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators |
AR103399A1 (es) | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3 |
US10196383B2 (en) | 2015-07-17 | 2019-02-05 | Sunshine Lake Pharma Co., Ltd. | Substituted quinazoline compounds and preparation and uses thereof |
PT4019022T (pt) | 2015-10-01 | 2024-03-11 | Biocryst Pharm Inc | Inibidores da calicreína plasmática humana |
WO2017088759A1 (en) | 2015-11-23 | 2017-06-01 | Sunshine Lake Pharma Co., Ltd. | OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF |
CA3059394C (en) | 2017-05-03 | 2023-09-12 | Idorsia Pharmaceuticals Ltd | Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives |
WO2019002344A1 (en) | 2017-06-29 | 2019-01-03 | Lonza Guangzhou Nansha Ltd. | PROCESS FOR THE PREPARATION OF ALPHA-METHYL-L-PROLINE |
WO2020007964A1 (en) | 2018-07-05 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives |
WO2020007977A1 (en) | 2018-07-06 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 7-trifluoromethyl-[1,4]diazepan derivatives |
CN108997308A (zh) * | 2018-07-09 | 2018-12-14 | 西藏大学 | 一种苯并咪唑类衍生物及其制备方法和应用 |
WO2020099511A1 (en) | 2018-11-14 | 2020-05-22 | Idorsia Pharmaceuticals Ltd | Benzimidazole-2-methyl-morpholine derivatives |
KR20230004670A (ko) | 2020-04-19 | 2023-01-06 | 이도르시아 파마슈티컬스 리미티드 | 다리도렉산트의 의학적 용도 |
WO2022166768A1 (zh) * | 2021-02-02 | 2022-08-11 | 南京明德新药研发有限公司 | 四氢吡咯并环化合物及其应用 |
CN115925699B (zh) * | 2022-02-25 | 2023-10-03 | 南京知和医药科技有限公司 | 具有镇痛活性的稠环化合物及其制备方法与用途 |
TW202400149A (zh) | 2022-05-13 | 2024-01-01 | 瑞士商愛杜西亞製藥有限公司 | 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物 |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3282927A (en) | 1964-05-21 | 1966-11-01 | Bristol Myers Co | 5-phenyl-4-thiazolylpenicillins |
AUPQ253199A0 (en) | 1999-08-30 | 1999-09-23 | Fujisawa Pharmaceutical Co., Ltd. | Non-prostanoid prostaglandin I2-agonist |
ES2238458T3 (es) | 2000-06-16 | 2005-09-01 | Smithkline Beecham Plc | Piperidinas para uso como antagonistas de los receptores de orexina. |
WO2002028839A1 (en) | 2000-10-06 | 2002-04-11 | Neurogen Corporation | Benzimidazole and indole derivatives as crf receptor modulators |
ES2234929T3 (es) | 2000-11-28 | 2005-07-01 | Smithkline Beecham Plc | Derivados de morfolina como antagonistas de los receptores de orexina. |
ATE383359T1 (de) | 2001-05-05 | 2008-01-15 | Smithkline Beecham Plc | N-aroyl zyklische amine |
AU2002341123A1 (en) | 2001-05-05 | 2002-11-18 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
WO2003002561A1 (en) * | 2001-06-28 | 2003-01-09 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
GB0127145D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
GB0130393D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
GB0130335D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
DE10240818A1 (de) | 2002-08-30 | 2004-05-13 | Grünenthal GmbH | Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate |
US20060040937A1 (en) | 2002-09-18 | 2006-02-23 | Glaxo Group Limited | N-aroyl cyclic amines as orexin receptor antagonists |
GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
GB0225938D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
GB0225884D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
AR044586A1 (es) | 2003-06-04 | 2005-09-21 | Aventis Pharma Sa | Productos aril - heteroaromaticos, composiciones que los contienen y su utilizacion |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
KR100848747B1 (ko) | 2004-03-01 | 2008-07-25 | 액테리온 파마슈티칼 리미티드 | 치환된 1,2,3,4-테트라하이드로이소퀴놀린 유도체 |
WO2005113522A1 (en) | 2004-05-07 | 2005-12-01 | Janssen Pharmaceutica, N.V. | Azole carboxamide inhibitors of bacterial type iii protein secretion systems |
EP1604989A1 (en) | 2004-06-08 | 2005-12-14 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | DPP-IV inhibitors |
US20060019975A1 (en) | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
GB0510142D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
HUP0500920A2 (en) | 2005-10-05 | 2007-07-30 | Richter Gedeon Nyrt | Oxadiazole derivatives, process for their preparation and their use |
JP4582722B2 (ja) | 2006-03-15 | 2010-11-17 | アクテリオン ファーマシューティカルズ リミテッド | 記憶機能を向上させるテトラヒドロイソキノリン誘導体 |
US8618102B2 (en) | 2006-07-14 | 2013-12-31 | Merck Sharp & Dohme Corp. | Bridged diazepan orexin receptor antagonists |
DE602007012910D1 (de) | 2006-08-15 | 2011-04-14 | Actelion Pharmaceuticals Ltd | Azetidinverbindungen als orexin-rezeptor-antagonisten |
WO2008038251A2 (en) * | 2006-09-29 | 2008-04-03 | Actelion Pharmaceuticals Ltd | 3-aza-bicyclo[3.1.0]hexane derivatives |
US8124623B2 (en) | 2006-11-10 | 2012-02-28 | Actelion Pharmaceuticals Ltd. | 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials |
PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
CL2007003827A1 (es) | 2006-12-28 | 2008-09-26 | Actelion Pharmaceuticals Ltd | Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras. |
WO2008087611A2 (en) | 2007-01-19 | 2008-07-24 | Actelion Pharmaceuticals Ltd | Pyrrolidine- and piperidine- bis-amide derivatives |
CL2008000836A1 (es) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
ES2351079T3 (es) | 2007-05-14 | 2011-01-31 | Actelion Pharmaceuticals Ltd. | Derivados de 2-ciclopropil-tiazol. |
US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8030495B2 (en) | 2007-05-23 | 2011-10-04 | Coleman Paul J | Cyclopropyl pyrrolidine orexin receptor antagonists |
GB0712888D0 (en) | 2007-07-03 | 2007-08-15 | Glaxo Group Ltd | Novel compounds |
PL2164847T3 (pl) | 2007-07-03 | 2012-02-29 | Actelion Pharmaceuticals Ltd | Związki 3-azabicyklo[3.3.0]oktanowe |
WO2009003993A1 (en) | 2007-07-03 | 2009-01-08 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
JP4361132B2 (ja) | 2007-07-05 | 2009-11-11 | パナソニック株式会社 | ロボットアームの制御装置及び制御方法、ロボット、及び制御プログラム |
AR067665A1 (es) | 2007-07-27 | 2009-10-21 | Actelion Pharmaceuticals Ltd | Derivados de trans-3- aza-biciclo ( 3.1.0) hexano |
ATE493386T1 (de) | 2007-07-27 | 2011-01-15 | Actelion Pharmaceuticals Ltd | Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate |
BRPI0814593A2 (pt) | 2007-07-27 | 2015-01-20 | Actelion Pharmaceuticals Ltd | Composto, composição farmacêutica que o contém e uso do composto. |
CA2699328A1 (en) | 2007-09-24 | 2009-04-02 | Actelion Pharmaceuticals Ltd | Pyrrolidines and piperidines as orexin receptor antagonists |
PE20091010A1 (es) | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | Derivados de tetrahidroquinolina |
PL2225231T3 (pl) | 2007-12-18 | 2012-01-31 | Actelion Pharmaceuticals Ltd | Pochodne aminotriazolu jako agoniści ALX |
RU2010138640A (ru) | 2008-02-21 | 2012-03-27 | Актелион Фармасьютиклз Лтд (Ch) | Производные 2-аза-бицикло [2.2.1] гептана |
GB0806536D0 (en) | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
CA2729985A1 (en) | 2008-07-07 | 2010-01-14 | Actelion Pharmaceuticals Ltd | Thiazolidine compounds as orexin receptor antagonists |
WO2010038200A1 (en) | 2008-10-01 | 2010-04-08 | Actelion Pharmaceuticals Ltd | Oxazolidine compounds as orexin receptor antagonists |
CN102164896A (zh) | 2008-10-14 | 2011-08-24 | 埃科特莱茵药品有限公司 | 苯乙基酰胺衍生物及其杂环类似物 |
JP2012506375A (ja) | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 2,5−二置換ピペリジンオレキシン受容体アンタゴニスト |
JP2012509910A (ja) | 2008-11-26 | 2012-04-26 | グラクソ グループ リミテッド | 新規の化合物 |
JP2012509911A (ja) | 2008-11-26 | 2012-04-26 | グラクソ グループ リミテッド | 新規の化合物 |
WO2010060472A1 (en) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Imidazopyridazine derivatives acting as orexin antagonists |
CN102300858A (zh) | 2008-12-02 | 2011-12-28 | 葛兰素集团有限公司 | N-{[(1r,4s,6r)-3-(2-吡啶基羰基)-3-氮杂双环[4.1.0]庚-4-基]甲基}-2-杂芳基胺衍生物及其用途 |
KR20110091582A (ko) | 2008-12-02 | 2011-08-11 | 글락소 그룹 리미티드 | N-{[1r,4s,6r-3-(2-피리디닐카르보닐)-3-아자비시클로[4.1.0]헵트-4-일]메틸}-2-헤테로아릴아민 유도체 및 그의 용도 |
GB0823467D0 (en) | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
JP2012522794A (ja) | 2009-04-03 | 2012-09-27 | メルク・シャープ・エンド・ドーム・コーポレイション | レニン阻害薬 |
AU2010240871A1 (en) | 2009-04-24 | 2011-10-27 | Glaxo Group Limited | 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists |
CN102414207B (zh) | 2009-06-09 | 2015-09-30 | 埃科特莱茵药品有限公司 | 氟化氨基三唑衍生物 |
WO2011050202A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
JP5847087B2 (ja) | 2009-10-23 | 2016-01-20 | ヤンセン ファーマシューティカ エヌ.ベー. | オレキシン受容体調節因子としての縮合複素環式化合物 |
KR101859409B1 (ko) | 2009-10-23 | 2018-05-18 | 얀센 파마슈티카 엔.브이. | 오렉신 수용체 조절제로서의 이치환된 옥타하이드로피롤로[3,4-c]피롤 |
EP2526092B1 (en) | 2010-01-19 | 2014-08-06 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
JP5744203B2 (ja) | 2010-08-24 | 2015-07-08 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | オレキシン受容体拮抗薬としてのプロリンスルフォンアミド誘導体 |
CN103249730A (zh) | 2010-09-24 | 2013-08-14 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
CN103201261A (zh) | 2010-11-10 | 2013-07-10 | 埃科特莱茵药品有限公司 | 用作为食欲素受体拮抗剂的内酰胺衍生物 |
EP2675801B1 (en) | 2011-02-18 | 2015-04-08 | Actelion Pharmaceuticals Ltd. | Novel pyrazole and imidazole derivatives useful as orexin antagonists |
UA112317C2 (uk) | 2011-11-08 | 2016-08-25 | Актеліон Фармасьютікалз Лтд | Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину |
TWI510481B (zh) | 2012-06-04 | 2015-12-01 | Actelion Pharmaceuticals Ltd | 苯并咪唑脯胺酸衍生物 |
AU2013328301A1 (en) | 2012-10-10 | 2015-05-28 | Actelion Pharmaceuticals Ltd | Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives |
JP2016510810A (ja) | 2013-03-12 | 2016-04-11 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | オレキシン受容体アンタゴニストとしてのアゼチジンアミド誘導体 |
UA119151C2 (uk) * | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
PT3077389T (pt) | 2013-12-03 | 2017-12-15 | Idorsia Pharmaceuticals Ltd | Forma cristalina de (s)-(2-(6-cloro-7-metil-1hbenzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona e a sua utilização como como antagonistas do receptor de orexina |
HUE040555T2 (hu) * | 2013-12-04 | 2019-03-28 | Idorsia Pharmaceuticals Ltd | Benzimidazol prolin származékok alkalmazása |
-
2013
- 2013-06-03 TW TW102119632A patent/TWI510481B/zh active
- 2013-06-03 PL PL13744805T patent/PL2855453T3/pl unknown
- 2013-06-03 NZ NZ703448A patent/NZ703448A/en unknown
- 2013-06-03 JP JP2015515624A patent/JP5814491B2/ja active Active
- 2013-06-03 AR ARP130101954 patent/AR091257A1/es active IP Right Grant
- 2013-06-03 EA EA201401351A patent/EA028046B1/ru not_active IP Right Cessation
- 2013-06-03 AU AU2013273222A patent/AU2013273222B2/en active Active
- 2013-06-03 US US14/405,649 patent/US9732075B2/en active Active
- 2013-06-03 MY MYPI2014703599A patent/MY169986A/en unknown
- 2013-06-03 SG SG10201702540UA patent/SG10201702540UA/en unknown
- 2013-06-03 ES ES13744805T patent/ES2617863T3/es active Active
- 2013-06-03 CN CN201380029097.2A patent/CN104334544B/zh active Active
- 2013-06-03 HU HUE13744805A patent/HUE031753T2/en unknown
- 2013-06-03 SG SG11201408004SA patent/SG11201408004SA/en unknown
- 2013-06-03 SI SI201330557A patent/SI2855453T1/sl unknown
- 2013-06-03 BR BR112014030173-5A patent/BR112014030173B1/pt active IP Right Grant
- 2013-06-03 LT LTEP13744805.6T patent/LT2855453T/lt unknown
- 2013-06-03 PT PT137448056T patent/PT2855453T/pt unknown
- 2013-06-03 DK DK13744805.6T patent/DK2855453T3/en active
- 2013-06-03 KR KR1020167019098A patent/KR101946128B1/ko active IP Right Grant
- 2013-06-03 KR KR1020157000154A patent/KR101689093B1/ko active IP Right Grant
- 2013-06-03 CA CA2873341A patent/CA2873341C/en active Active
- 2013-06-03 TW TW104132248A patent/TWI570120B/zh active
- 2013-06-03 WO PCT/IB2013/054567 patent/WO2013182972A1/en active Application Filing
- 2013-06-03 MX MX2014014885A patent/MX354102B/es active IP Right Grant
- 2013-06-03 KR KR1020187029604A patent/KR101995683B1/ko active IP Right Grant
- 2013-06-03 EA EA201600366A patent/EA029899B1/ru not_active IP Right Cessation
- 2013-06-03 EP EP13744805.6A patent/EP2855453B1/en active Active
-
2014
- 2014-11-14 PH PH12014502540A patent/PH12014502540A1/en unknown
- 2014-12-02 IL IL236024A patent/IL236024A/en active IP Right Grant
- 2014-12-02 CL CL2014003294A patent/CL2014003294A1/es unknown
- 2014-12-19 ZA ZA2014/09422A patent/ZA201409422B/en unknown
-
2015
- 2015-09-16 HK HK15109034.2A patent/HK1208449A1/xx unknown
-
2017
- 2017-02-28 CY CY20171100269T patent/CY1118735T1/el unknown
- 2017-03-02 HR HRP20170351TT patent/HRP20170351T1/hr unknown
- 2017-07-07 US US15/644,547 patent/US10329287B2/en active Active
-
2019
- 2019-05-07 US US16/405,797 patent/US11040966B2/en active Active
-
2022
- 2022-08-31 LT LTPA2022518C patent/LTPA2022518I1/lt unknown
- 2022-09-01 HU HUS2200040C patent/HUS2200040I1/hu unknown
- 2022-09-13 FR FR22C1047C patent/FR22C1047I2/fr active Active
- 2022-09-28 NL NL301197C patent/NL301197I2/nl unknown
- 2022-10-27 NO NO2022044C patent/NO2022044I1/no unknown